The response of isolated blood vessels to a variety of vasoactive agonists is modulated by the presence of endothelial cells. Indeed, these cells can release both dilator and constrictor substances. The major endothelium-derived relaxing factor may be nitric oxide, which activates soluble guanylate cyclase in the smooth muscle, although the endothelial cells also secrete an unidentified hyperpolarizing factor. Among the natural stimuli for the release of endotheliumderived relaxing factors are circulating hormones, platelet products, thrombin, shear stress, and certain autacoids. Endothelium-derived relaxing factors may contribute to the regulation of the release of atrial natriuretic factor and renin. The endothelial cells can also release constricting factors; among the likely candidates are superoxide anions or the peptide endothelin. In hypertensive blood vessels, the ability to release endothelium-derived relaxing factors but not endothelium-derived contracting factors is blunted. (Hypertension 1989;13:658-667) A fter the initial report by Furchgott and Zawadzki 1 of the obligatory role of endothelial cells in relaxations of isolated arteries of the rabbit to acetylcholine, vascular physiologists and pharmacologists have been forced to admit that the most intimal layer of the blood vessel wall, in addition to its role in metabolism, coagulation, and transport processes, possesses the ability to profoundly modulate the degree of contraction of the smooth muscle that surrounds it. It does so primarily by the release of short-lived vasodilator and vasoconstrictor substances, termed endotheliumderived relaxing factor (EDRF) and endotheliumderived contracting factor (EDCF), respectively. The ability of the endothelium to control the underlying vascular smooth muscle appears to be an ancestral property of these cells, emerging early in evolution (see Reference 2). This brief review summarizes the author's current thinking on the questions concerning endothelium-dependent modulation-the answers to which could be of particular relevance in hypertension and its treatment.
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The endothelium-dependent responsiveness to acetylcholine (or to other endothelium-dependent vasoactive agents) is not fixed, as it can be modulated chronically by hemodynamic variables or hormonal status. 1213 Chronic modulation by hemodynamic variables may explain why, in animals and in humans, the endothelium-dependent responses to acetylcholine (and other endothelium-dependent dilators) are considerably blunted in peripheral veins compared with those in arteries. 16 it is uncertain whether endothelium-derived acetylcholine contributes to vascular regulation.
Catecholamines
Substances circulating in the blood would be potential candidates for the triggering of endotheliumdependent responses. Circulating catecholamines (epinephrine and norepinephrine) are no exception. Indeed, endothelial cells, at least in large blood vessels carrying oxygenated blood, contain a 2 -adrenergic receptors that, when activated, can evoke endothelium-dependent relaxations of the underlying smooth muscle (Figure 4) . 17 -20 Hence, it is likely that « 2 -adrenergic endothelium-dependent effects of the catecholamines contribute to the vasodilator effects that they have in the coronary circulation or the splanchnic bed. Theoretically, such endotheliumdependent responses could contribute to the vasodilator and hence the hypotensive effect of a 2 -adrenergic agonists like clonidine ( Figure 5 ). In addition, the endothelium-dependent relaxation to a 2 -adrenergic agonists can be potentiated by @-adrenergic blocker carteolol (Figure 6 ), which implies that part of the (unexplained) vasodilator effect of ]8-blockers may be due to facilitation of endothelium-dependent relaxation of arterial smooth muscle. 
Other Hormones
Vasopressin and oxytocin cause endotheliumdependent relaxations of the canine basilar artery without doing so in peripheral arteries; this implies that activation of endothelial vasopressin receptors may contribute to the preferential perfusion of the brain during acute volume depletion (Figure 7 ).
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Platelets, Platelet-Derived Products, and Thrombin
When isolated blood vessels are exposed to aggregating platelets, they contract (constrict) vigorously, mainly because their smooth muscle reacts to the direct activating effect of 5-hydroxytryptamine (serotonin) and thromboxane A 2 released from the platelets. However, if platelet aggregation is induced in the vicinity of an isolated coronary artery that contains endothelial cells, the ensuing contraction is very limited; if the aggregation is initiated when the vascular smooth muscle is already activated, it causes further contraction in arteries without endothelium but profound relaxations in arteries with endothelium ( Figure 8 ). 923 - 25 In the dog, platelet-activating factor contributes little to the platelet-induced responses. 26 The ability of the endothelium to respond to intraluminal platelet products and to relax the underlying smooth muscle 27 is only part of the role it plays in trying to prevent obstruction of blood flow in normal blood vessels (see below). Its role may be reinforced whenever the coagulation cascade is activated, with the resulting formation of thrombin, a potent trigger for endothelium-dependent relaxation in most blood vessels ( Figure 10 ). 8 30 Hence, it is not surprising that, in the presence of a concentration of the peptide that does not evoke measurable endothelium-dependent responses per se, the inhibitor of converting enzyme trandolaprilat causes marked endothelium-dependent relaxation ( Figure  11 ). This then implies that the (unexplained) vasodilator effect of the inhibitors of converting enzyme may be related to the unmasking of endotheliumdependent dilatations to endogenous bradykinin.
Shear Stress
It has been known for decades that, when flow increases through large arteries, dilatation ensues ("flow-induced vasodilatation"). It is now established that this phenomenon is endothelium dependent and can be attributed to the release of EDRF (see below) caused by an increase in shear stress. 24 Whether this is due secondarily to the release of autacoids (acetylcholine, ATP, serotonin, or substance P) 31 by certain endothelial cells affecting their immediate neighbors or to direct activation of all endothelial cells by shear stress is uncertain.
How Do the Endothelial Cells Control the Underlying Vascular Smooth Muscle?
Nitric Oxide In view of current physiological knowledge, there are only two major possible mechanisms by which the endothelium could act as a modulator of the responsiveness of the medial smooth muscle. The first one would be cell-to-cell contacts with induction of electrical signals. 32 Although this remains a distinct possibility at the microcirulatory level where the attachment of endothelial cells to vascular smooth muscle is particularly intimate, it is now established that, in large blood vessels, the message from the endothelium consists'of a potent but shortlived substance (EDRF). 33 - 35 Cultured endothelial cells maintain the ability to release the vasodilator mediator.
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38 It had been known for several years that relaxations by EDRF are accompanied by an accumulation of cyclic guanosine 5'-monophosphate in the vascular smooth muscle. 39 - 41 This cellular action of EDRF is similar to that exerted by nitric oxide (NO), the final mediator of the relaxing response to the nitrosovasodilators. NO shares with EDRF the property to be exquisitely sensitive to destruction by superoxide anion. 3742 Thus, it has been proposed that EDRF may be nothing other than NO (Figure 12) . 4344 experiments, the biologic and physiochemical properties of NO and EDRF were indistinguishable. 45 It seems probable that NO originates from the metabolites of L-arginine. 46 Whether NO is released as such or is bound to a precursor molecule remains a matter of debate.
Is Nitric Oxide the Only Answer?
Early in the description of endothelium-dependent relaxations, it appeared plausible that the endotheAcetylcholine Endothelial FIGURE 
Sketch showing canine native endothelial cells exposed to acetylcholine and the resulting activation of muscarinic receptors (M) (see Figure 3) that causes them to secrete at least two factors. One factor causes hyperpolarization of smooth muscle and is called endothelium-derived hyperpolarizingfactor (EDHF). The other is called endothelium-derived relaxing factor (EDRF) and presumably is nitric oxide (NO); it causes relaxation of vascular smooth muscle by activating soluble fraction of enzyme guanylate cyclose, leading to accumulation of cyclic guanosine 5'-monophosphate (cGMP).
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FIGURE 13. Sketch showing two endothelium-derived relaxing factors (EDRFs) being released in cultured porcine endothelial cells. Ouabain prevents action of one and release of the other (which presumably is nitric oxide [NO]). ADP, adenosine 5'-diphosphate and A23187, calcium ionophore.
Hum could release more than one relaxing factor. 28 It is now established that, in addition to NO (which does not alter the membrane potential of smooth muscle cells), at least certain endothelial cells release a distinct factor causing hyperpolarization of the underlying vascular smooth muscle; this factor has been called endothelium-derived hyperpolarizing factor (EDHF) (Figure 12 ). 47 - 49 Pharmacological analysis of the responses to acetylcholine has demonstrated that the muscarinic receptor mediating the release of EDHF differs from that responsible for the release of EDRF (Figure 3) . 48 Experiments in isolated canine blood vessels and in cultured porcine endothelial cells 38 ( Figure 13 ) (U. Hoeffner and P.M. Vanhoutte, unpublished observations) demonstrated also that endothelial cells can release at least two distinct EDRFs. Interestingly, ouabain inhibits the action of one factor on vascular smooth muscle and the release of the other (which most likely is NO) (Figure 13 ). These observations may have implications in the understanding of the vasoconstrictor effects of endogenous inhibitors of Na + ,K + exchanges if these play a role in the genesis of certain types of hypertension.
In addition, the endothelium can produce adenosine, ammonia, and prostacyclin, all of which can cause relaxation of vascular smooth muscle. However, although all these substances can be considered as EDRFs, none of them cause hyperpolarization of canine arterial smooth muscle (K. Komori and P.M. Vanhoutte, unpublished observations).
Does the Endothelium Release Contracting Factors?
While investigating the responses of arteries and veins to endothelium-dependent relaxing agents, it became apparent that in certain blood vessels, certain of these agents caused endotheliumdependent contractions rather than relaxations.
14 Two types of endothelium-dependent contractions have been identified. In peripheral veins and cerebral arteries, contractions evoked by arachidonic acid, the Ca 2+ ionophore A23187, and even acetylcholine appear to require the presence of the endothelium and the activity of cyclooxygenase. 50 -51 A likely candidate as mediator of this type of endothelium-dependent contraction is superoxide anion (Figure 14) . 52 In a number of isolated arteries and veins, endothelium-dependent contractions can be evoked by anoxia 14 -53 -55 ; the contractions can be inhibited by Ca 2+ -antagonists, presumably because of their action on vascular smooth muscle rather than on the endothelial cells. 55 Although the mediator of the endotheliumdependent hypoxic contraction is unknown, the possibility exists that the hypoxic endothelial cells may release a vasoconstrictor peptide like endothelin ( Figure M) ."-^." EDRF and NO inhibit the adhesion and the aggregation of platelets; their antiplatelet activity is considerably augmented in the presence of prostacyclin and vice versa. 58 -* 2 The synergistic action of prostacyclin and EDRF at the interface between the plasma and the blood vessel wall probably contributes substantially to the antiaggregating properties of the endothelium (Figure 9 ).
The endothelial cells, which possess many hormonal receptors with unknown function, also may constitute a link in the feedback loops controlling hormonal secretion. This is suggested by the observations that inhibitors of endothelium-dependent relaxations augment the basal release of atrial natriuretic peptide from the rat atrium (C. Sanchez-Ferrer and P.M. Vanhoutte, unpublished observations). EDRF markedly inhibits the basal release of renin (Figure 15) may be a regulator of the release of the hormone and possibly constitutes the intrarenal baroreceptor that links increases in shear stress in the afferent arterioles with the deactivation of the secretory cells of the juxtaglomerular apparatus.
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What Is the Relevance for Hypertension?
Most authors agree that, in a variety of experimental models of hypertension, the responsiveness of isolated large arteries to acetylcholine and other endothelium-dependent relaxing agents is reduced (Figure 16 ; e.g., References 64-68). A similar conclusion has been reached for small arteries and resistance vessles. 69 In salt-induced hypertension, the reduced endothelium-dependent relaxations are due to the combination of a diminished release of EDRF and a lesser sensitivity of the vascular smooth muscle to the relaxing effect of the factor ( Figure  17 ). 68 In that type of hypertension, a normal endothelium-dependent responsiveness can be restored by appropriate antihypertensive treatment or by dietary adjustments in potassium intake.
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In the spontaneously hypertensive rat, the reduction in endothelium-dependent relaxation cannot be due to a reduced release of EDRF but to the liberation of a constricting factor by the endothelial cells ( Figure  18 ). 67 The release of the factor involved requires the activation of cyclooxygenase (Figure 17) . 67 Higher concentrations of serotonin also cause endothelium contractions in the aorta of the spontaneously hypertensive rat, which may explain why the endothelium is rather ineffective in preventing contractions to aggregating platelets in this blood vessel. Thus, in hypertension and in other cardiovascular diseases, 4 the ability of the endothelium to release EDRFs is blunted, while, if anything, its ability to release EDCFs is augmented ( Figure 17 ). It is tempting to assume that this imbalance may contribute to the increase in peripheral resistance characteristic of the disease.
